Ash 2020 cell therapy preview – the battle for recognition
With many of the usual targets on display Fate, Celyad, Allovir and others look to maintain momentum.
Ash 2020 preview – early winners and losers
Unveiling of abstracts for December’s haematology meeting sent Crispr up and Allogene down, but the biggest beneficiary was private.
Crispr valuation is no match for reality
A patient death overshadowed the first data from a human trial of the company’s allogeneic Car-T therapy CTX110.
